Compare SD & NNNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SD | NNNN |
|---|---|---|
| Founded | 2006 | 2021 |
| Country | United States | Germany |
| Employees | N/A | 27 |
| Industry | Oil & Gas Production | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 502.8M | 417.8M |
| IPO Year | 2006 | N/A |
| Metric | SD | NNNN |
|---|---|---|
| Price | $13.92 | $10.12 |
| Analyst Decision | Strong Sell | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $15.00 | N/A |
| AVG Volume (30 Days) | ★ 246.0K | 33.6K |
| Earning Date | 05-05-2026 | 04-07-2026 |
| Dividend Yield | ★ 3.07% | N/A |
| EPS Growth | ★ 12.43 | N/A |
| EPS | ★ 0.50 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $12.65 | N/A |
| Revenue Next Year | $1.75 | N/A |
| P/E Ratio | ★ $27.20 | $446.57 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.89 | $8.30 |
| 52 Week High | $18.45 | $54.90 |
| Indicator | SD | NNNN |
|---|---|---|
| Relative Strength Index (RSI) | 48.02 | 37.56 |
| Support Level | $13.26 | $8.30 |
| Resistance Level | $13.99 | $29.98 |
| Average True Range (ATR) | 0.29 | 1.31 |
| MACD | 0.03 | 0.58 |
| Stochastic Oscillator | 42.62 | 33.89 |
SandRidge Energy Inc is a United States-based oil and natural gas company. It is engaged in the exploration, development, and production of crude oil, natural gas, and Natural gas liquids. Business activities of the group include Exploration and Production, Drilling and Oil Field Services, and Midstream Gas Services. The company's primary areas of operation are the Mid-Continent in Oklahoma and Kansas.
Anbio Biotechnology is a medical device company focused on in vitro diagnostics. The company's mission is to change the diagnostics market by personalizing and decentralizing the current diagnostic solutions for faster diagnosis to improve patient prognosis. The company proposes this by providing accessible and affordable diagnostic solutions globally at the forefront of science and offering laboratory, wellness, at-home, and point-of-care (POCT) in vitro diagnostic (IVD) solutions. The business planning is to focus on validating and commercializing the existing portfolio of in vitro diagnostic products, as well as generating additional data required to support regulatory submissions and compliance, including under frameworks such as the In Vitro Diagnostic Regulation (IVDR).